ARX788 in HER2-positive Metastatic Breast Cancer Patients

计划入组 44 人 · 首次发布于 2024 年 10 月 29 日

A Study of Patients With HER2-Positive Metastatic Breast Cancer

计划入组 1,000 人 · 首次发布于 2005 年 3 月 15 日

Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

计划入组 23 人 · 首次发布于 2011 年 1 月 26 日

Margetuximab(Margenza)

Rx

Pertuzumab(Perjeta, Perjeta-Herceptin, Phesgo)

HER2+ Breast Cancer(Diakonos)

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

Novel Treatment Strategy Shows Promise for HER2-Positive Metastatic Breast Cancer Patients

Novel HER2-Targeted Therapies Show Promise in Advanced Breast Cancer

Zanidatamab and Evorpacept Combination Shows Promise in HER2+ Breast Cancer